Literature DB >> 11422767

Influence of various hemodialysis membranes on the plasma (1-->3)-beta-D-glucan level.

H Kanda1, K Kubo, K Hamasaki, Y Kanda, A Nakao, T Kitamura, T Fujita, K Yamamoto, T Mimura.   

Abstract

BACKGROUND: Recently, invasive fungal infections have increased significantly because of the growing number of immunocompromised hosts. The measurement of plasma (1-->3)-beta-D-glucan has been proposed as a useful diagnostic tool for deep mycosis. In this study, we analyzed the alteration of the plasma (1-->3)-beta-D-glucan concentration by using different kinds of hemodialysis (HD) membranes in end-stage renal disease (ESRD) patients and estimated its half-life.
METHODS: Twenty-seven patients with ESRD without known fungal infections (with a median age of 66 years old) were enrolled in this study. Cellulose triacetate (CTA) membrane, cellulose (Cu) membrane, and polymethyl methacrylate (PMMA) membrane were used in three consecutive initiations of HD and plasma (1-->3)-beta-D-glucan concentration was measured before and after each HD session.
RESULTS: The level did not change between before and after HD when CTA and PMMA membranes were used. In contrast, the plasma (1-->3)-beta-D-glucan level increased greatly after HD using the Cu membrane (from 9.4 to 332 pg/mL in median). Hypothesizing that the plasma (1-->3)-beta-D-glucan level declines exponentially, its median half-life is estimated at 20 hours, which is not affected by hepatic or renal function.
CONCLUSIONS: Because the plasma (1-->3)-beta-D-glucan level increases dramatically after HD using the Cu membrane, dialyzers with Cu membrane should be avoided for HD in patients with suspected deep mycosis. The measurement of plasma (1-->3)-beta-D-glucan is also useful for the patients with hepatic or renal failure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422767     DOI: 10.1046/j.1523-1755.2001.00802.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  28 in total

1.  Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting.

Authors:  John F Mohr; Charles Sims; Victor Paetznick; Jose Rodriguez; Malcolm A Finkelman; John H Rex; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

2.  How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors.

Authors:  H Hammarström; N Kondori; V Friman; C Wennerås
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-09       Impact factor: 3.267

3.  Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit.

Authors:  G Lo Cascio; R Koncan; G Stringari; A Russo; A Azzini; A Ugolini; M Ligozzi; E Polati; G Cornaglia; E Concia; V Schweiger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-13       Impact factor: 3.267

Review 4.  Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis.

Authors:  James A Grubbs; John W Baddley
Journal:  Curr Rheumatol Rep       Date:  2014-10       Impact factor: 4.592

5.  Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections.

Authors:  Jerry W Pickering; Howard W Sant; Catherine A P Bowles; William L Roberts; Gail L Woods
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

6.  Reactivity of (1-->3)-beta-d-glucan assay with commonly used intravenous antimicrobials.

Authors:  Francisco M Marty; Colleen M Lowry; Steven J Lempitski; David W Kubiak; Malcolm A Finkelman; Lindsey R Baden
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

7.  High plasma concentration of beta-D-glucan after administration of sizofiran for cervical cancer.

Authors:  Hirokazu Tokuyasu; Kenichi Takeda; Yuji Kawasaki; Yasuto Sakaguchi; Noritaka Isowa; Eiji Shimizu; Yasuto Ueda
Journal:  Int J Gen Med       Date:  2010-10-05

8.  Use and limits of (1-3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis.

Authors:  Annie Sulahian; Raphael Porcher; Anne Bergeron; Sophie Touratier; Emmanuel Raffoux; Jean Menotti; Francis Derouin; Patricia Ribaud
Journal:  J Clin Microbiol       Date:  2014-04-16       Impact factor: 5.948

9.  Usage of 1,3-β-D-Glucan for Early Detection of Invasive Mycoses and Outcome Parameter in Immunocompromised Critically Ill Patients.

Authors:  Tobias Lahmer; Jürgen Held; Sebastian Rasch; Christopher Schnappauf; Analena Beitz; Roland M Schmid; Wolfgang Huber
Journal:  Mycopathologia       Date:  2016-09-12       Impact factor: 2.574

10.  Combined assessment of beta-D-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients.

Authors:  Yoshio Takesue; Masayuki Kakehashi; Hiroki Ohge; Yuuji Imamura; Yoshiaki Murakami; Masaru Sasaki; Masahiko Morifuji; Yujiro Yokoyama; Mohei Kouyama; Takashi Yokoyama; Taijiro Sueda
Journal:  World J Surg       Date:  2004-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.